Fairvalue-Calculator Fairvalue-Calculator
EN DE

Chong Kun Dang Pharmaceutical Corp (185750) Fair Value & Analysis

Healthcare · KR · Market cap 933B KRW

Price66,900 KRW
Fair Value115,734 KRW
Upside+73.0%
Quality95/100
Evidence: Medium Range 81,014 KRW – 150,454 KRW

Fair value as of: Jun 24, 2026

Analysis

Chong Kun Dang Pharmaceutical Corp (185750) currently trades at 66,900 KRW, while our model-based Fair Value estimate is 115,734 KRW — implying the stock looks roughly 73.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in 1941 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Chong Kun Dang Pharmaceutical Corp (185750) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 115,734 KRW versus a price of 66,900 KRW — about +73% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 185750?
Our 21-model fair value for Chong Kun Dang Pharmaceutical Corp is 115,734 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 66,900 KRW.
What is the quality score of 185750?
Chong Kun Dang Pharmaceutical Corp has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.